

Evaluation of urine biomarkers of kidney injury in polycystic kidney disease

Chirag R. Parikh^{1,2}, Neera K. Dahl¹, Arlene B. Chapman³, James E. Bost⁴, Charles L. Edelstein⁵, Diane M. Comer⁴, Raoul Zeltner¹, Xin Tian¹, Jared J. Grantham⁶ and Stefan Somlo^{1,7}

¹Department of Medicine (Nephrology), Yale University School of Medicine, New Haven, Connecticut, USA; ²Clinical Epidemiology Research Center, VAMC, West Haven, Connecticut, USA; ³Section of Nephrology, Emory University, Atlanta, Georgia, USA; ⁴Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; ⁵Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado, USA; ⁶Division of Nephrology, University of Kansas, Kansas City, Kansas, USA and ⁷Department of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA

Progressive disruption of renal tubular integrity in the setting of increased cellular proliferation and apoptosis is a feature of autosomal dominant polycystic kidney disease (ADPKD). Here we evaluated the effect of these processes on the expression of *Lcn2* (NGAL) and interleukin (IL)-18, markers of tubular injury, in rodent models and in the cyst fluid and urine of patients with ADPKD. Two mouse models where *Pkd2* was inactivated, which resulted in early- or adult-onset cysts, were used to evaluate NGAL levels. Further, the Han:SPRD rat model of polycystic disease was used to study IL-18 levels. In four annual serial urine samples collected from 107 patients with ADPKD in the Consortium for Radiologic Imaging for the Study of Polycystic Kidney Disease (CRISP) study, NGAL and IL-18 excretion rates were determined in conjunction with measures of total kidney volume and estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease equation. Kidneys from affected mice and rats showed prominent expression of NGAL and IL-18/IL-18R, respectively, in epithelial cells lining kidney cysts. In human ADPKD cyst fluid, both NGAL and IL-18 were elevated. In CRISP patients, the mean percentage increase in total kidney volume was 5.4/year and the mean decline in eGFR 2.4 ml/min/year. The trend of increased mean urine NGAL and IL-18 over 3 years was statistically significant; however, there was no association between tertiles of IL-18 or quartiles of NGAL and change in total kidney volume or eGFR over this period. Thus, urinary NGAL and IL-18 excretion is mildly and stably elevated in ADPKD, but does not correlate with changes in total kidney volume or kidney function. This may be due, in part, to the lack of communication between individual cysts and the urinary collecting system in this disorder.

Kidney International (2012) **81**, 784–790; doi:10.1038/ki.2011.465; published online 18 January 2012

KEYWORDS: biomarker; IL-18; NGAL surrogate

Correspondence: Chirag R. Parikh, Section of Nephrology, Yale University and VAMC, 950 Campbell Avenue, Mail Code 151B, Building 35 A, Room 219, West Haven, Connecticut 06516, USA. E-mail: chirag.parikh@yale.edu

Received 28 April 2011; revised 17 October 2011; accepted 2 November 2011; published online 18 January 2012

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, affecting 1:500 to 1:1000 people, and is the fourth leading cause of end-stage renal disease in the United States.¹ ADPKD is characterized by massively enlarged kidneys caused by lifelong cyst expansion and is associated with a late decline in kidney function progressing to renal failure in the majority of patients.^{2,3} Cyst growth requires processes of cell proliferation, fluid secretion, and remodeling of the surrounding milieu. A broad range of mechanisms have been proposed to underlie these changes, and the apically located primary cilium, a single hair-like organelle protruding into the luminal space, has been implicated as being central to the altered intracellular signaling processes responsible for increased cellular proliferation and apoptosis.^{4,5}

Specific therapies for ADPKD are lacking,^{6,7} and one of the challenges in both clinical care and trial design is the absence of appropriate biomarkers to monitor disease progression early in the course of disease before significant impairment of renal function occurs. Currently, magnetic resonance imaging-based total kidney volume (TKV) measurements detect early progression. However, magnetic resonance imaging is expensive, TKV measures are not yet automated, and structural progression as evidenced by magnetic resonance imaging may lag behind important intrarenal functional changes. Importantly, clinical measures of kidney dysfunction, such as elevated serum creatinine concentration, occur late in the disease and are inadequate with regard to identification of worsening cystic disease measured by TKV in the early stages.⁸ Therefore, non-invasive biomarkers developed for diagnostic purposes or that accurately identify increased renal cyst burden or increased TKV as well as progressive kidney damage are important. Identification of such markers could also assist in identification of patients at increased risk for progression to end-stage renal disease and could be utilized to determine the therapeutic benefit of an intervention.

Urine interleukin (IL)-18 and urine NGAL activity are established biomarkers of acute and chronic kidney injury.⁹ These are biomarkers of proximal and distal tubular injury

and ADPKD is a chronic tubulointerstitial disorder. Given that tubular disruption and cyst formation are key features of ADPKD, we tested the hypothesis that levels of urinary NGAL and IL-18 are higher in PKD kidneys and correlate with increased TKV, decreased kidney function, faster rates of increase in TKV, and decline in kidney function. In order to test this hypothesis, we conducted series of preclinical experiments to establish the presence of IL-18 and NGAL in PKD models. In addition, urinary IL-18 and NGAL concentrations were measured in patients from the Consortium for Radiologic Imaging for the Study of Polycystic Kidney Disease (CRISP) study, where a large cohort of ADPKD patients with relatively intact kidney function were studied in a prospective longitudinal manner with regard to changes in TKV and kidney function or estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease equation.^{10,11}

RESULTS

Preclinical studies

Two orthologous gene mouse models based on *Pkd2* inactivation were used to examine NGAL (*Lipocalin 2* (*Lcn2*)) expression in cystic and non-cystic tissues. Adult *Pkd2*^{WS25/-} mice¹² showed strong expression of *Lcn2* transcripts detected by *in situ* hybridization in cyst-lining cells (Figure 1a–c). Weaker *Lcn2* expression was also present in some pericystic tubules that appeared otherwise normal (Figure 1a and b). The second postnatal orthologous gene cystic model combined a novel transgenic mouse line expressing the human *PKD2* sequence from the *pCAGGS* vector¹³ (*pCAGGS-PKD2*) with the previously described *Pkd2*^{-/-} null mice that are embryonically lethal.¹⁴ Transgenic expression of *PKD2* in *Pkd2*^{-/-}; *pCAGGS-PKD2* mice partially rescued the embryonic lethality, cardiac defects, and left-right axis formation defects observed in *Pkd2*^{-/-} mice^{14,15} (data not shown). Surviving mice develop markedly cystic kidneys during postnatal life (Figure 1d) due to failure of the transgene to reconstitute expression of *PKD2* in kidney tissues. Immunocytochemical staining of cystic kidneys with antisera against NGAL¹⁶ showed localization of the *Lcn2* protein product in the epithelial cells lining the walls of the majority of cysts in *Pkd2*^{-/-}; *pCAGGS-PKD2* mice (Figure 1e and f). A similar pattern of cyst-associated NGAL expression was found in kidneys from *Pkd2*^{WS25/-} animals (data not shown), although there was significant variation in expression within both models (Figure 1).

IL-18 and IL-18-receptor (IL-18R) expression was examined in the Han:SPRD (Cy/+) cystic rats at 1 year of age. Cyst-lining epithelial cells showed strong expression of IL-18 (Figure 2a) and IL-18R was expressed in a subset of cells in regions surrounding the cysts (Figure 2b).

Human cyst fluid

The levels of NGAL and IL-18 in the five pooled cystic fluid samples are provided in Table 1. Both NGAL and IL-18 levels

are highly elevated compared with both serum and urine concentrations in normal subjects or in patients with acute kidney injury.^{17,18}

Longitudinal patient studies

Urine samples were available at baseline in 209 of 241 CRISP participants. The mean age of these CRISP participants was 32.1 years and 41.2% were male. The baseline mean eGFR was 89.39 ml/min per 1.73 m² and the mean TKV was 1080 ml range (308–3196 ml). Urine samples were available for 156 participants at year 1, for 133 at year 2, and for 211 at year 3. Urine samples were collected from 107 patients at baseline and all three follow-up visits.

The urinary NGAL and IL-18 raw concentration levels at baseline and follow-up visits are given in Figure 3. The majority of patients demonstrated levels considered to be within the normal range or low at baseline, with approximately 35% and 16% of patients with levels >20 U/ml for NGAL and IL-18, respectively. Only 7% and 2% of patients had levels of NGAL and IL-18, respectively, >100 U/ml, similar to the levels seen in patients with acute kidney injury.^{17–20}

Table 2 demonstrates that among those with biomarker data at every visit, the corrected and uncorrected biomarker levels change over 3 years. Tests for a linear and quadratic trend over 3 years in both biomarker levels (corrected and uncorrected) were statistically significant ($P \leq 0.05$), implying an initial increase in the levels, which then dropped in years 2 and 3.

Biomarkers and outcomes. Baseline tertiles for biomarker concentrations and biomarkers corrected for creatinine concentrations of IL-18 and quartiles for NGAL were not associated with percent change in TKV or change in eGFR at 3 years of follow-up (Tables 3a and 3b). No associations were found between baseline TKV and eGFR or change in TKV or eGFR over time when grouped by detectable versus not detectable limits (≥ 10 pg/ml for IL-18 and ≥ 1 ng/ml for NGAL; data not shown).

DISCUSSION

In our series of preclinical and clinical studies we demonstrated that NGAL and IL-18 are present and highly expressed in the epithelial cells lining kidney cysts. We also found that urinary NGAL and IL-18 excretion were mildly and constantly elevated in ADPKD and change over time, but did not correlate with worsening in kidney function or increase in TKV. The discrepant findings between cyst epithelial expression and fluid versus urinary excretion of these biomarkers are possibly due to the lack of communication between the cystic space and the urinary collecting system. It is well known that renal cysts in ADPKD kidneys detach from the parent nephron soon after reaching 2 cm in diameter. Some patients had very high levels in the urine, which may be related to acute fluctuations in these cytokines that occur during periods of rapid cyst expansion. As such, annual measurements in TKV may not be sufficiently sensitive to detect changes associated with acute cyst




Figure 1 | Expression of *Lcn2* (NGAL) in orthologous gene mouse models of polycystic kidney disease. (a–c) RNA *in situ* hybridization for *Lcn2* in a *Pkd2*^{W525/-} cystic kidney showing expression (dark reactivity) after hybridization with the *Lcn2*-specific antisense RNA probe (a, b) in epithelial cyst-lining cells and in some pericystic tubules; (c) the sense probe lacks reactivity. The boxed area in panel a is shown in higher magnification in panel b (inset is digitally enlarged). (d) The appearance of kidneys from *Pkd2*^{-/-};pCAGGS-PKD2 mice at postnatal day 10. (e, f) Immunocytochemistry showing expression of NGAL in cyst-lining epithelia of *Pkd2*^{-/-};pCAGGS-PKD2 mice (NGAL, green; α -tubulin, red; 4',6-diamidino-2-phenylindole, blue). Original magnifications: (a, c) $\times 10$; (b) $\times 40$; (e, f) $\times 20$.




Figure 2 | Interleukin (IL)-18 expression in Han:SPRD (Cy/+) rats. (a) Immunocytochemistry showing strong expression of IL-18 (green) in cells lining the cysts in 1-year-old Han:SPRD (Cy/+) rats. (b) IL-18 receptor expression (red) is also observed in cells adjacent to some cysts. Staining is also seen in the nucleus and interstitium. 4',6-diamidino-2-phenylindole, blue. Original magnification, $\times 400$.

Table 1 | NGAL and IL-18 concentrations in the cyst fluid obtained during nephrectomy in PKD patients

Kidney status at nephrectomy	Age	Gender	NGAL (ng/ml) ^a	IL-18 (pg/ml) ^a
SCr: 1.7; prior transplant; no dialysis	60	M	140	100
SCr: 8.5; dialysis	54	F	4939	380
SCr: 4.4; dialysis	46	F	979	152
SCr: 5.1; prior transplant; no dialysis	54	M	449	309
SCr: NA; no dialysis; ESRD	49	F	3625	588

Abbreviations: ESRD, end-stage renal disease; IL-18, interleukin-18; NA, not applicable; SCr, serum creatinine.

^aUrinary levels of IL-18 and NGAL are usually <25 pg/ml and <20 ng/ml, respectively in healthy adults.

expansion. Also, eGFR in the majority of these ADPKD patients remained stable, consistent with the natural history of this disorder. Typically cyst expansion is relatively slow, with detectable changes in size limited to 6 months in most

ADPKD patients.²¹ Capturing patients with acute rapid rates of cyst expansion (i.e., during acute cyst hemorrhage) may demonstrate the usefulness of these markers.

NGAL expression increases in renal epithelial cells in response to injury.²² Increases in urinary NGAL levels have been found to be predictive of acute kidney injury in patients undergoing cardiac surgery and in other hospitalized settings.^{9,18} NGAL gene expression is also increased in human ADPKD-derived cell lines and tissue,²³ in the HAN:SPRD (cy/+) rat model of ADPKD,²⁴ and in the *cpk* mouse model of recessive PKD.²⁵ Thus, NGAL emerged as a potentially interesting biomarker of progression in ADPKD. In the present study, NGAL (*Lcn2*) was found to be highly expressed in two distinct orthologous mouse models of ADPKD. This increased expression is seen at both the mRNA and protein level and is associated with the cells lining the cysts in these mouse models.

Urinary IL-18 is elevated during apoptosis and necrosis of renal tubular cells, which is associated with acute kidney




Figure 3 | Biomarker distribution in the Consortium for Radiologic Imaging for the Study of Polycystic Kidney Disease cohort at each visit. Raw values of (a) interleukin-18 values are in pg/ml and (b) NGAL values are in ng/ml.

Table 2 | Biomarker values over time for 107 participants who followed up for all visits

Variable	Baseline visit			1-year follow-up			2-year follow-up			3-year follow-up		
	Mean	s.d.	Median	Mean	s.d.	Median	Mean	s.d.	Median	Mean	s.d.	Median
Urine IL-18 (ng/ml) ^a	13.8	26.7	1.0	23.5	58.2	1.0	9.3	24.0	1.0	8.4	19.5	1.0
Urine NGAL (pg/ml) ^a	32.3	52.7	14.3	43.2	86.7	11.3	20.2	42.9	6.2	19.5	29.5	10.6
Urine creatinine (mg/ml)	0.9	0.7	0.8	1.0	0.6	1.0	0.8	0.6	0.7	1.0	0.6	0.9
NGAL/creatinine (ng/mg) ^a	37.6	51.2	16.1	40.0	64.9	11.4	27.4	37.4	13.4	22.9	34.3	10.3
IL-18/creatinine (pg/mg) ^a	13.0	18.8	5.3	19.7	42.4	3.2	8.4	12.5	3.4	7.2	13.1	1.9

Abbreviation: IL-18, interleukin-18.

^a $P \leq 0.05$ for linear and quadratic trend and Friedman's chi-squared test.

injury in rodent and human studies.^{26,27} Given that apoptosis contributes to the pathogenesis of cyst formation in ADPKD,²⁸ we measured IL-18 and its receptor levels in

murine and human renal cysts. IL-18 expression was prominent in the cystic epithelial cells in kidneys of 1-year-old Han:SPRD (Cy/+) rats. As IL-18 signals via the IL-18R,

Table 3a | Mean annual % change in total kidney volume and eGFR at 1 year and 3 years from baseline by IL-18 tertile

Baseline IL-18 tertile	1-year % TKV change		
	N	Mean	s.d.
≤1	127	4.12	6.61
>1 and <19	37	4.95	7.83
≥19 and ≤434	39	5.66	5.66
Baseline IL-18 tertile	3-year % TKV change		
	N	Mean	s.d.
≤1	126	16.40	14.17
>1 and <19	37	19.93	16.54
≥19 and ≤434	38	17.11	12.65
Baseline IL-18 tertile	1-year % eGFR change		
	N	Mean	s.d.
≤1	127	−2.57	15.86
>1 and <19	37	−0.55	12.68
≥19 and ≤434	39	−7.13	13.16
Baseline IL-18 tertile	3-year % eGFR change		
	N	Mean	s.d.
≤1	127	−8.16	18.23
>1 and <19	37	−5.76	14.39
≥19 and ≤434	38	−12.25	17.12

Abbreviations: eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; TKV, total kidney volume.

No significant differences by baseline IL-18 tertile for TKV or eGFR changes.

the expression of IL-18R in the epithelial cells lining the cysts suggests that IL-18 may be having a biological effect during cyst formation or expansion. IL-18 and NGAL levels are also highly enriched in cyst fluid derived from ADPKD patients, demonstrating translation of the findings from murine and rat models to human disease. This prompted us to evaluate whether IL-18 and NGAL had clinical utility as biomarkers for progression of ADPKD using samples from the CRISP cohort.

The results of the current study are in contrast to the results from Bolignano *et al.*,²⁹ in which 26 patients with ADPKD were evaluated by serum and urinary measurements of NGAL. Urinary and serum NGAL levels were higher in patients with ADPKD compared with controls, and proportionately higher in those patients with advanced disease. However, the patients with ADPKD already had a substantial reduction in renal function with a mean creatinine clearance of 59 ± 38 ml/min, which is far lower than the value obtained for the CRISP population studied here and lower than that obtained for the control group (115 ± 32 ml/min). It is possible that the elevations in serum and urinary NGAL concentrations found in this study were related more to the level of renal dysfunction than to the presence of renal cystic disease. Thus, NGAL may have utility as a biomarker during later stages of ADPKD in the event of a decline in glomerular filtration rate associated with advanced ADPKD disease.

Table 3b | Mean annual % change in total kidney volume and eGFR at 1 year and 3 years from baseline by NGAL quartile

Baseline NGAL quartile	1-year % TKV change		
	N	Mean	s.d.
<3.65	51	5.24	7.69
≥3.65 and <11.5	48	4.43	6.42
≥11.5 and <31.6	53	3.38	6.73
≥31.6 and ≤315.62	51	5.26	5.73
Baseline NGAL quartile	3-year % TKV change		
	N	Mean	s.d.
<3.65	50	18.98	14.80
≥3.65 and <11.5	50	17.20	13.70
≥11.5 and <31.6	51	15.42	15.10
≥31.6 and ≤315.62	50	17.15	13.99
Baseline NGAL quartile	1-year % eGFR change		
	N	Mean	s.d.
<3.65	51	−1.93	15.27
≥3.65 and <11.5	48	−1.98	15.87
≥11.5 and <31.6	53	−7.23	14.81
≥31.6 and ≤315.62	51	−0.94	13.27
Baseline NGAL quartile	3-year % eGFR change		
	N	Mean	s.d.
<3.65	51	−5.83	17.30
≥3.65 and <11.5	50	−9.10	17.00
≥11.5 and <31.6	51	−12.59	17.79
≥31.6 and ≤315.62	50	−6.42	17.25

Abbreviations: eGFR, estimated glomerular filtration rate; IL-18, interleukin-18; TKV, total kidney volume.

No significant differences by baseline NGAL quartile for TKV or eGFR changes.

Although we conducted a systematic evaluation of the kidney injury biomarkers in both pre-clinical and clinical settings of ADPKD, there are few limitations to consider. NGAL and IL-18 are relatively stable through multiple freeze-thaw cycles and the levels are known to be stable for at least 3 years at -80°C . In addition, we have found predictable results with these biomarkers in other studies where samples were collected and stored for several years, so it is likely that these biomarkers were stable in PKD urine samples.¹⁹ Although the samples were handled uniformly across the study visits, the reasons for the fall in the biomarker levels during the follow-up period were unclear. Other potential biomarkers for progression in ADPKD include monocyte chemoattractant protein-1,³⁰ B-N-acetylhexosaminidase,³¹ and KIM-1.³² Kistler *et al.*³³ found that a unique urinary proteomic profile and pathway could correctly identify patients with ADPKD. It is possible that a combination of urinary biomarkers as opposed to a single biomarker could predict disease progression better in PKD.

MATERIALS AND METHODS

Preclinical studies

Animals and tissue samples. Three mouse strains based on *Pkd2* inactivation and one rat model of autosomal dominant

proximal cystic disease were used. NGAL experiments utilized the mouse strains *Pkd2*^{WS2512} and *Pkd2*^{WS183} (null allele, a.k.a., *Pkd2*^{-/-})¹⁴ and a novel transgenic mouse line expressing the human *PKD2* sequence from the *pCAGGS* vector¹³ (*pCAGGS-PKD2*). Cystic kidneys were obtained from 8-week-old *Pkd2*^{WS2512/-} mice and 10-day-old *Pkd2*^{-/-}; *pCAGGS-PKD2* mice. One year old polycystic Han:SPRD (Cy/+) rats were used for IL-18 studies.³⁴

RNA in situ hybridization. For *in situ* hybridization, serial cryostat sections (4–5 µm) of snap-frozen kidneys were mounted on aminopropylsilane-coated slides and fixed with 4% paraformaldehyde. After acetylation, the slides were prehybridized at 42 °C in 45% formamide, 0.6 mol/l NaCl, 2.5 × Denhardt's solution, 10 mmol/l Tris-HCl, 1 mmol/l EDTA, 0.1% SDS, and 0.15 mg/ml transfer RNA. Digoxigenin-labeled *Lcn2*-specific anti-sense (and sense control) riboprobes were generated by *in vitro* transcription and hybridized to the sections dissolved in pre-hybridization solution containing an additional 10% dextran sulfate at 42 °C for 16 h. The slides were then washed in 50% formamide/1 × standard sodium citrate at 55 °C treated with RNase, and washed twice in 0.1 × standard sodium citrate at room temperature. Signal was detected by an antibody reaction to digoxigenin according to the manufacturer's protocol (Roche, Nutley, NJ). Sections were lightly counterstained with hematoxylin and photographed using a Nikon TE2000U microscope (Nikon, Tokyo, Japan).

Immunocytochemistry. Kidneys were obtained from anesthetized mice by perfusion fixation with 0.4% lidocaine and 0.01% heparin followed by 4% paraformaldehyde in phosphate-buffered saline. Sections 4–5 µm thick were blocked with 0.1% bovine serum albumin/10% goat serum in phosphate-buffered saline for 1 h at room temperature and incubated with primary antibodies overnight at 4 °C followed by the secondary antibodies for 1 h at room temperature. Images were obtained with a Nikon TE2000U inverted microscope. The polyclonal antibody to lipocalin-2 was a kind gift from Jonathan Barasch (Columbia University, New York) and was applied at a dilution of 1:500.¹⁶ Anti-α-tubulin antibody was obtained from Sigma (St Louis, MO). Secondary antibodies were conjugated with Cy5 or Cy3.

For immunofluorescence of rat samples, kidney tissues were embedded in Tissue-Tek OCT Compound (Sakura, Alphen aan den Rijn, The Netherlands), snap-frozen in liquid nitrogen, and stored at –80 °C. Cryostat sections (5 µm) were fixed in 70% acetone/30% methanol and prepared for immunofluorescence studies as previously described.³¹ A rabbit polyclonal IL-18 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, catalogue number sc-7954) antibody was used.

Clinical studies

Human kidney cyst samples. Samples of cyst fluid were collected from several cysts and pooled in each of five ADPKD nephrectomy specimens. All participants had established renal insufficiency or were receiving renal replacement therapy. The indications for nephrectomy in these patients were symptoms including pain, shortness of breath, early satiety, increases in abdominal girth, or as a requirement in preparation for renal transplantation. Cyst fluid was obtained at the time of surgery and aliquoted and stored at –20 °C immediately.

CRISP cohort: longitudinal studies of human ADPKD. These protocols were reviewed by the CRISP Ancillary Studies committee and were approved by the CRISP Steering committee and the Yale Institutional Review Board. The CRISP Consortium is an

NIH-funded UO1 cooperative agreement that began in 2000. Two hundred and forty one ADPKD participants with relatively intact kidney function (creatinine clearance > 70 ml/min) with two-thirds at increased risk for progression to renal failure were enrolled. Participants were studied on an annual basis in a standardized fashion as reported elsewhere.¹¹ Urine samples were obtained from CRISP participants in the fasting state as a first void at baseline and at each annual visit for 3 consecutive years. The samples were handled uniformly across enrolling sites as per the study protocol. The urine samples were centrifuged immediately after collection; the supernatant was separated, aliquoted, and frozen at –80 °C until assays were performed. No protease inhibitors or other additives were added to the urine samples after collection. Samples underwent one freeze-thaw cycle before biomarker measurement.

Biomarker assays. Specimens were randomly ordered for biochemical analysis, and the personnel performing the biochemical assays were blinded to clinical information and subject identification. The urine NGAL enzyme-linked immunosorbent assay was performed as described previously for urine and cyst fluid.¹⁸ Briefly, microtiter plates precoated with a mouse monoclonal antibody raised against human NGAL (HYB211-05, AntibodyShop, Gentofte, Denmark) were blocked with buffer containing 1% bovine serum albumin, coated with 100 µl of patient samples, and incubated with a biotinylated monoclonal antibody against human NGAL (HYB211-01B, AntibodyShop) followed by addition of avidin-conjugated HRP (Dako, Carpinteria, CA). Tetramethylbenzidine substrate (BD Biosciences, San Jose, CA) was added for color development, which was read after 30 min at 450 nm with a microplate reader (Benchmark Plus, BioRad, Hercules, CA). The inter- and intra-assay coefficient variations were 5% and 10%, respectively, for samples analyzed on the same day. Urine creatinine was measured using a quantitative colorimetric assay kit (Sigma). IL-18 was measured in human urine and cyst fluid using a human IL-18 ELISA kit (Medical and Biologic Laboratories, Nagoya, Japan) that specifically detects the mature form of IL-18 as described previously.¹⁷ The coefficients of variation of inter- and intra-assay reproducibility for IL-18 concentration were 7% and 10%, respectively. Measurements of IL-18 and NGAL concentrations were repeated on 10% of randomly chosen samples to confirm the reliability of the measurement.

Statistical analysis

The data were examined using SAS system software (SAS Institute, Cary, NC). Although 241 ADPKD patients were enrolled in CRISP, not every participant completed all 3 years of study, and in select individuals urine samples were either not available or the participant was pregnant and the urine sample was not appropriate for use. When comparing levels over time within individuals, we restricted the sample to the 107 patients who had results available at every visit.

Urine NGAL and IL-18 biomarker levels were measured at each study visit. TKV was measured using magnetic resonance imaging, details of which are provided in the CRISP protocol, and the Modification of Diet in Renal Disease formula was used to estimate eGFR. To assess change in TKV and eGFR, we calculated the percent change at each year from baseline. To test for a linear or quadratic trend, a general linear model with repeated measures was used and the results were supplemented with Friedman's test owing to the skewed distribution of the data. Baseline urine biomarkers were grouped by quartile for NGAL and by tertile for IL-18. Analysis of variance was used to test for differences in TKV and Modification of Diet in Renal Disease glomerular filtration rate by IL-18 tertiles and

NGAL quartiles. As seen below, IL-18 concentrations were undetectable in over 50% of participants. To address data inclusion for all subjects, all raw IL-18 values were increased by 1 to avoid zero values.

DISCLOSURE

CRP and CLE are co-inventors on a patent filed by the University of Colorado Health Sciences Center for use of IL-18 protein for diagnosis and treatment of acute renal failure.

ACKNOWLEDGMENTS

We thank Dr Devarajan's laboratory for measuring NGAL in the study samples. The studies were supported by the Pilot Grant to NKD and CRP from the Yale PKD Center (DK57328), CRISP UO1 consortium grant, and R01 DK54053 (SS).

REFERENCES

- Vicente ET, Peter CH, Yves P. Autosomal dominant polycystic kidney disease. *Lancet* 2007; **369**: 1287–1301.
- Piontek K, Menezes LF, Garcia-Gonzalez MA et al. A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1. *Nat Med* 2007; **13**: 1490–1495.
- Grantham JJ, Cook LT, Wetzel LH et al. Evidence of extraordinary growth in the progressive enlargement of renal cysts. *Clin J Am Soc Nephrol* 2010; **5**: 889–896.
- Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. *Adv Chronic Kidney Dis* 2010; **17**: 118–130.
- Veland IR, Awan A, Pedersen LB et al. Primary cilia and signaling pathways in mammalian development, health and disease. *Nephron Physiol* 2009; **111**: p39–p53.
- Walz G, Budde K, Mannaa M et al. Everolimus in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2010; **363**: 830–840.
- Serra AL, Poster D, Kistler AD et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. *N Engl J Med* 2010; **363**: 820–829.
- Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. *Clin J Am Soc Nephrol* 2006; **1**: 148–157.
- Coca SG, Yalavarthy R, Concato J et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. *Kidney Int* 2008; **73**: 1008–1016.
- Chapman AB, Guay-Woodford LM, Grantham JJ et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. *Kidney Int* 2003; **64**: 1035–1045.
- Grantham JJ, Torres VE, Chapman AB et al. Volume progression in polycystic kidney disease. *N Engl J Med* 2006; **354**: 2122–2130.
- Wu G, D'Agati V, Cai Y et al. Somatic inactivation of Pkd2 results in polycystic kidney disease. *Cell* 1998; **93**: 177–188.
- Miyazaki J, Takaki S, Araki K et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. *Gene* 1989; **79**: 269–277.
- Wu G, Markowitz GS, Li L et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. *Nat Genet* 2000; **24**: 75–78.
- Pennekamp P, Karcher C, Fischer A et al. The ion channel polycystin-2 is required for left-right axis determination in mice. *Curr Biol* 2002; **12**: 938–943.
- Yang J, Goetz D, Li JY et al. An iron delivery pathway mediated by a lipocalin. *Mol Cell* 2002; **10**: 1045–1056.
- Parikh CR, Jani A, Melnikov VY et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. *Am J Kidney Dis* 2004; **43**: 405–414.
- Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. *Lancet* 2005; **365**: 1231–1238.
- Parikh CR, Abraham E, Ancukiewicz M et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. *J Am Soc Nephrol* 2005; **16**: 3046–3052.
- Haase M, Bellomo R, Devarajan P et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **54**: 1012–1024.
- Serra AL, Kistler AD, Poster D et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSSE ADPKD study. *BMC Nephrol* 2007; **8**: 13.
- Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. *J Am Soc Nephrol* 2003; **14**: 2534–2543.
- Husson H, Manavalan P, Akmaev VR et al. New insights into ADPKD molecular pathways using combination of SAGE and microarray technologies. *Genomics* 2004; **84**: 497–510.
- Riera M, Burtsey S, Fontes M. Transcriptome analysis of a rat PKD model: importance of genes involved in extracellular matrix metabolism. *Kidney Int* 2006; **69**: 1558–1563.
- Mrug M, Zhou J, Woo Y et al. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. *Kidney Int* 2008; **73**: 63–76.
- Melnikov VY, Faubel S, Siegmund B et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. *J Clin Invest* 2002; **110**: 1083–1091.
- Parikh CR, Mishra J, Thiessen-Philbrook H et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. *Kidney Int* 2006; **70**: 199–203.
- Golav B. Apoptosis in polycystic kidney disease. *Biochim Biophys Acta (BBA) Mol Basis Dis* 2011; **1812**: 1272–1280.
- Bolignano D, Coppolino G, Campo S et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. *Am J Nephrol* 2007; **27**: 373–378.
- Zheng D, Wolfe M, Cowley Jr BD et al. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2003; **14**: 2588–2595.
- Dursun B, He Z, Somerset H et al. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. *Am J Physiol Renal Physiol* 2006; **291**: F578–F587.
- Kuehn EW, Park KM, Somlo S et al. Kidney injury molecule-1 expression in murine polycystic kidney disease. *Am J Physiol Renal Physiol* 2002; **283**: F1326–F1336.
- Kistler AD, Mischak H, Poster D et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. *Kidney Int* 2009; **76**: 89–96.
- Zafar I, Belibi FA, He Z et al. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD). *Nephrol Dial Transplant* 2009; **24**: 2349–2353.